Lupus Foundation of America

Lupus Foundation of America

Founded in 1977, the Lupus Foundation of America operates from Washington, DC, as the largest US nonprofit dedicated solely to lupus. Rather than managing an endowment from a single wealth origin, the organization funds its mission through corporate partnerships, individual donations, and structured giving vehicles, including a cryptocurrency donation program and a beneficial interest in a perpetual trust. CEO Louise Vetter serves as the public face of an entity that blends patient services with direct research funding. Grantmaking concentrates on investigator-initiated biomedical research, translational science, and advocacy for accelerated regulatory pathways. Corporate alliances supply a material share of program revenue: GSK provides educational grants, AstraZeneca sponsors research and education programs, and Aurinia Pharmaceuticals — developer of a lupus nephritis therapy — collaborates on treatment advocacy. The organization's posture is not investor-like; it deploys capital as a funder and convener, with money market instruments serving treasury functions. Geographic reach is fully domestic, coordinated through the Washington headquarters and a network of local chapters. The national board draws operational expertise from outside nonprofit management. Theresa Juday of CVS Health and Brian Antonsen of McKinstry bring supply-chain and commercial real-estate perspectives, respectively. The foundation maintains accreditation from the BBB Wise Giving Alliance, a four-star rating from Charity Navigator, and certification through the National Health Council — each signaling a governance standard more typical of regulated financial entities than disease-specific charities. No dedicated investment team or internal CIO role is disclosed. Structurally, the Lupus Foundation of America functions as a hybrid: part public-health funder, part patient-advocacy organization. Unlike family offices or healthcare endowments with discretionary pools, it does not maintain a separate investment portfolio or make venture-style allocations into biotech. Its influence flows instead through research agenda-setting, clinical-trial design input, and the relationships its corporate partners cultivate for market access and regulatory insight.